GÜLİN ÖZTÜRK ÖZKAN, GÜLGÜN ERSOY, Akın DAYAN

İnsülin Direnci Olan Hastaların Antropometrik Ölçümleri ve Biyokimyasal Bulgularının Değerlendirilmesi

Amaç: Bu çalışma, insülin direnci tanısı alan hastaların antropometrik ölçümleri ve biyokimyasal bulgularını değerlendirmek amacıyla yapılmıştır. Bireyler ve Yöntem: Ekim 2011-Nisan 2012 tarihleri arasında, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Dahiliye Polikliniğine zayıflamak amacıyla gelen 30-50 yaşları arasında, ilk kez insülin direnci teşhisi konulan, hiperlipidemi dışında başka bir hastalığı bulunmayan, 53 kadın hastaya kişisel ve hastalık bilgilerini içeren bir anket uygulanmıştır. Hastaların rutin biyokimyasal bulguları ve insülin direncine ait biyokimyasal bulgularına bakılmış, HOMA-IR (Homeostatis Model Assessment-Insulin Resistance) değerleri hesaplanmış ve bazı antropometrik ölçümleri yapılmıştır. Bulgular: Araştırma sonunda hastaların vücuttaki yağ miktarı, yağ yüzdesi ve bel çevresi değerlerinin yüksek olduğu saptanmıştır. Hastaların açlık kan trigliserit, yüksek dansiteli lipoprotein (HDL) kolesterol, glukoz, tokluk glukoz, açlık insülin ve tokluk insülin değerlerinin normal sınırlar içinde, açlık düşük dansiteli lipoprotein (LDL)-kolesterol ve çok düşük dansiteli lipoprotein (VLDL) kolesterol değerlerinin normalin üst sınırına yakın, total kolesterol değerlerinin normalin üst sınırında, HOMA-IR değerlerinin normal sınırın üzerinde olduğu görülmüştür. Sonuç: İnsülin direnci olan hastalarda BKİ, vücuttaki yağ miktarı, yağ yüzdesi, bel çevresi, HOMA-IR değerlerinin yüksek, açlık glukoz, tokluk glukoz, açlık insülin, tokluk insülin, açlık kan trigliserit, total kolesterol, HDL-kolesterol, LDL-kolesterol, VLDL-kolesterol değerlerinin normal düzeyde olduğu saptanmıştır. Obez hastaların HOMA-IR değerinin hesaplanması, insülin direnci olan hastaların erken dönemde yakalanmasını sağlayacaktır.

Assessment of Anthropometric Measurements and Biochemical Findings in Patients with Insulin Resistance

Aim: The aim of this study was to assess the anthropometric measurements and biochemical findings in patients with insulin resistance. Subjects and Methods: This study was conducted on 53 female patients, aged 30-50 years, for the first time insulin resistance diagnosed, having no disease other than hyperlipidemia, body mass index (BMI) between 30-40 kg/m2 admitted to Haydarpaşa Numune Education and Research Hospital Internal Medicine Outpatient Clinic, between October 2011 and April 2012. A questionaire on personal and disease information was applied to these patients. Biochemical parameters were examined, some anthropometric measurements were taken, and HOMA-IR (Homeostatis Model Assessment-Insulin Resistance) values were calculated. Results: It was found that BMI, fat mass, percentage of fat, waist circumference of patients were above normal levels. Triglycerides, high density lipoprotein (HDL) cholesterol, plasma fasting glucose, postprandial glucose, fasting insulin and postprandial insulin levels were within normal limits; low density lipoprotein (LDL) cholesterol and very low density lipoprotein (VLDL) cholesterol levels were close to upper limits; total cholesterol level was at upper limit; HOMA-IR levels were above normal. Conclusion: In patients with insulin resistance, BMI, body fat, fat percentage, waist circumference, HOMA-IR values were higher; fasting glucose, postprandial glucose, fasting insulin, postprandial insulin, blood levels of fasting triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol levels were found to be at normal levels. So calculation of HOMA-IR in obese patients, patients with insulin resistance will be captured in the early period.

PDF

___

1.Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112(12):1821-1830.
2.Fernández-Real JM, Straczkowski M, Vendrell J, Soriguer F, del Pulgar SP, Gallart L, et. Al. Protection from inflammatory disease in insulin resistance: the role of manan-binding lectin. Diabetologia 2006;49:2402- 2411.
3.Gülcü F, Parmaksız A, Kıdır M, Gürsu MF. Metabolik sendrom. Fırat Sağlık Hizmetleri Dergisi 2006;1(3):23- 32.
4.Büyüktuncer Z, Köksa, G, Dağdelen S, Geyik PÖ, Işıldak M Erbaş T, et. al. Metabolik sendromda peroksizom proliferatoaktive edici gamma (PPARγ) Pro12AIa genotipinin sendrom bileşenlerine etkisi ve diyet ile etkileşimi. Turk J Endoc Metab 2010;14:54-59.
5.Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clinl Endocrinol Metab 2008;93(11):S64-S73.
6.Jager J, Gtrémeaux T, Cormon M, Le Marchand- Brustel Y, Tanti JF. Interluekin-1β-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007;148(1):241-251.
7.Caballero B. Introduction: Obesity in developing countries. J Nutr 2001;131:866S-870S.
8.Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu MY, Smith EO, et. al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: The impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004;89(6):2697-2703.
9.McAuley K, Mann J. Nutritional determinants of insulin resistance. J Lipid Res 2006;47:1668-1676.
10.Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory snydrome. Endocr Rev 2003;24(3):278-301.
11.McQuaid SE, Hodson L, Neville MJ, Dennis AL, Cheeseman J, Humphreys SM, et al. Downregulation of adipose tissue fatty acid trafficking in obesity. Diabetes 2011;60:47-55.
12.Fernandez ML. The metabolic syndrome. Nutr Rev 2007;65(6):S30-S34.
13.Després JP, Brewer B. Metabolic syndrome: the dysmetabolic state of dysfunctional adipose tissue and insulin resistance. Eur Heart J Suppl 2008;10 (Supplement B):B1-B3.
14.Kashyap SR, Defronzo RA. The insulin resistance syndrome: physiological considerations. Diab Vasc Dis Res 2007;4(1):13-19.
15.Adaş M, Özbey N, Metin N, Yaraşır H, Kazancıoğlu R, Molvalılar S, et al. Şişman kadınlarda viseral yağ indeksi ve metabolik risk göstergeleri ile ilişkisi. İstanbul Tıp Fakültesi Mecmuası 1999;62(3):311-314.
16.Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93(11):S57-S63.
17.Manigrasso MR, Ferroni P, Santilli F, Taraborelli T, Guagnan, MT, Michetti N, et al. Association between circulating adiponectin and interleukin-10 levels in android obesity: Effects of weight loss. J Clin Endocrinol Metab 2005;90(10):5876-5879.
18.Ertürk H. İnsülin direnci nedir? http://www.e- doktorunuz.com/makale.asp?id=86 Erişim Ağustos 22, 2013.
19.WHO: Measuring obesity-classification and Description of anthropometric data. Report on a WHO consultation on the epidemiology of obesity, Warsaw, 21-23, October 1987.
20.Pekcan G. (2011). Hastanın Beslenme Durumunun Saptanması. A. Baysal (Ed.) Diyet El Kitabı (S. 61- 107). Ankara: Hatipoğlu Yayınları.
21.SPSS For Windows Release 11.0 (2004).
22.Hawley JA. Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab Res Rev 2004;20:383-393.
23.Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich- Horvat P, Liu CY, et. al. Abdominal visceral and subcutaneous adipose tissue compartments. Association with metabolic risk factors in the framingham heart study. Circulation 2007;116:39-48.
24.Vega GL, Adams-Huet B, Peshock R, Willett DW, Shah B, Grundy SM. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab 2006;91(11):4459-4466.
25.Solomon TPJ, Haus JM, Kelly KR, Cook MD, Filion J, Rocco M, et al. A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans. Am J Clin Nutr 2010;92:1359-1368.
26.Goodpaster BH, Krishnaswami S, Harris TB, Katsiaras A. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 2005;165:777-783.
27.Bağrıaçık N, Onar H, İlhan B, Tarakçı T, Oşar Z, Özyazar M, et al. Obesity profile in Turkey. Int J Diabetes Metab 2009;17:5-8.
28.Kuk JL, Lee S, Heymsfield SB, Ross R. Wiast circumference and abdominal adipose tissue distribution: influence of age and sex. Am J Clin Nutr 2005;81:1330-1334.
29.Hozowa A, Jacobs DR, Steffes MW, Gross MD, Steffen LM, Lee DH. Associations of serum carotenoid concentrations with the development of diabetes and with insulin concentration: Interaction with smoking. Am J Epidemiol 2006; 163(10):929-937.
30.Czernichow S, Vergnaud AC, Galan P, Arnaud J, Favier A, Faure H, et al. Effect of long-term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic snydrome in adults. Am J Clin Nutr 2009;90:329-335.
31.Costarelli L, Muti E, Malavolta M, Cipriano C, Giacconi R, Tesei S, et al. Distinctive modulation of inflammatory and metabolic parameters in relation to zinc nutritional status in adult overweight/obese sunjects. J Nutr Biochem 2010;21:432-437.
32.Kim DJ, Xun P, Liu K, Loria C, Yokota K, Jacobs DR, et al. Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diab Care 2010;33(12):2604-2610.
33.Marreiro DN, Geloneze B, Tambascia MA, Lerário AC, Halpern A, Cozzolino SMF. Effect of zinc supplementation on serum leptin levels and insulin resistance of obese women. Biol Trace Elem Res 2006;112:109-118.
34.Selçuk MT, Selçuk H, Çelenk MK, Maden O, Özeke Ö, Korkmaz Ş, et al. Sol ana koroner hastalığın genç ve yaşlı hastalarda klinik özellikler ve risk faktörleri açısından değerlendirilmesi. TGKD 2007;11(1):17-23.
35.Aktimur SH, Yılmazer TT, Süher MM. Glukoz metabolizması ile antropometrik ve biyokimyasal ölçümler arasındaki ilişkinin değerlendirilmesi. Yeni Tıp Dergisi 2011;28(2):105-108.